The role of inflammation in the pathogenesis of heart failure

被引：17

作者：

Lisman K.A. ^{[1
]}

Stetson S.J. ^{[1
]}

Koerner M.M. ^{[1
]}

Farmer J.A. ^{[1
]}

Torre-Amione G. ^{[1
]}

机构：

[1] Department of Medicine, Section of Cardiology, Baylor College of Medicine, 6550 Fannin, Suite 1901, Houston

来源：

Current Cardiology Reports | 2002年 / 4卷 / 3期

关键词：

Heart Failure; Left Ventricular Ejection Fraction; Chronic Heart Failure; Left Ventricular Assist Device; Tumor Necrosis Factor Receptor;

D O I：

10.1007/s11886-002-0051-3

中图分类号：

学科分类号：

摘要：

Heart failure is not a simple defect in the pumping function of cardiac muscle, but rather a complex systemic inflammatory disease affecting many organ systems. Recognition of this fact has led to new therapeutic interventions such as angiotensin-converting enzyme inhibitors and b-blockers, which have a significant impact on the quality of life and survival of patients with heart failure. During the course of heart failure, the steps involved in the activation of inflammation are now better understood. As a result, new therapies will develop that block, modify, or prevent these inflammatory changes, and supplement our armamentarium for providing better and longer lives for patients. © 2002 by Current Science Inc.

引用

页码：200 / 205

页数：5

共 22 条

[1]

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med, 327, pp. 685-691, (1992)

[2]

Pfeffer M.A., Braunwald E., Moye L.A., Et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The save investigators, N Engl J Med, 327, pp. 669-677, (1992)

[3]

Eichhorn E.F., Bristow M.R., The carvedilol prospective randomized cumulative survival (copernicus) trial, Curr Control Trials Cardiovasc Med, 2, pp. 20-23, (2001)

[4]

Torre-Amione G., Kapadia S., Lee J., Et al., Expression and functional significance of tumor necrosis factor receptors in human myocardium, Circulation, 92, pp. 1487-1493, (1995)

[5]

Torre-Amione G., Kapadia S., Lee J., Et al., Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart, Circulation, 93, pp. 704-711, (1996)

[6]

Torre-Amione G., Kapadia S., Benedict C., Et al., Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (solvd), J Am Coll Cardiol, 27, pp. 1201-1206, (1996)

[7]

Bozkurt B., Torre-Amione G., Soram O.Z., Et al., Results of a multidose phase i trial with tumor necrosis factor receptor (p75) fusion protein (entanercept) in patients with heart failure, J Am Coll Cardiol, 34, pp. 177-180, (1999)

[8]

Deswal A., Bozkurt B., Seta Y., Et al., Safety and efficacy of a soluble p75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure, Circulation, 99, pp. 3224-3226, (1999)

[9]

Louis A., Cleland J.G., Crabbe S., Et al., Clinical trials update: Capricorn, copernicus, miracle, staf, ritz-2, recover and renaissance and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the american college of cardiology, 2001, Eur J Heart Fail, 3, pp. 381-387, (2001)

[10]

Torre-Amione G., Stetson S.J., Youker K.A., Et al., Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery, Circulation, 100, pp. 1189-1193, (1999)

← 1 2 3 →